Caplin Point Laboratories Ltd has signed a Memorandum of Understanding (MoU) committing an investment of ₹925 crore to establish four new state-of-the-art pharmaceutical manufacturing units in Tamil Nadu.
The agreement was formalized at the Tamil Nadu Investors’ Conclave in Chennai in the presence of the Hon’ble Chief Minister of Tamil Nadu, Mr. C. Joseph Vijay. On behalf of Caplin Point Laboratories Ltd, Dr. Sridhar Ganesan (Managing Director) and Mr. D. Muralidharan (Whole Time Director) officially signed and handed over the MoU documents.
Under this strategic expansion, Caplin Point will set up four specialized facilities across the state, with dedicated units focusing on high-value segments including Biologics & Biosimilars as well as Hormone Injectables. This capital outlay is aimed at scaling the company’s research, development, and sterile manufacturing capabilities to meet growing global demand for affordable and critical healthcare formulations.
In addition to improving the regional pharmaceutical ecosystem, this major investment initiative is projected to generate approximately 2,400 new employment opportunities across Tamil Nadu, fostering technical skill development and economic growth within the state.
The initiative reinforces Caplin Point Laboratories’ ongoing commitment to enhancing healthcare access, strengthening domestic supply chains, and driving scalable manufacturing excellence across complex therapeutic categories including sterile injectables, oncology, and advanced APIs.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
